Hanmi Pharm’s targeted lung cancer treatment is indicated as the FDA’s Breakthrough Therapy
Hanmi Pharm announced on the 21st that the US FDA selected HM61713(BI code name: BI1482694), developed by Hanmi Pharm, as the ‘breakthrough therapy’ of lung cancer. HM61713 is a targeted lung cancer treatment in which Hanmi Pharm established a global license agreement(excluding Korea, China and H...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
